Drug
Allo 501a
Allo 501a: highest development phase Phase 1/2, developed by Allogene Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Allogene Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALLO-501A NCT04416984 | Phase 1/2 | Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma |
Latest
No recent events.
Follow Allo 501a on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.